JP2025504431A5 - - Google Patents
Info
- Publication number
- JP2025504431A5 JP2025504431A5 JP2024542183A JP2024542183A JP2025504431A5 JP 2025504431 A5 JP2025504431 A5 JP 2025504431A5 JP 2024542183 A JP2024542183 A JP 2024542183A JP 2024542183 A JP2024542183 A JP 2024542183A JP 2025504431 A5 JP2025504431 A5 JP 2025504431A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- residue
- sars
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2022/000035 | 2022-01-17 | ||
| PCT/IB2022/000035 WO2023135439A1 (en) | 2022-01-17 | 2022-01-17 | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
| PCT/EP2023/051025 WO2023135333A1 (en) | 2022-01-17 | 2023-01-17 | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504431A JP2025504431A (ja) | 2025-02-12 |
| JP2025504431A5 true JP2025504431A5 (enExample) | 2026-01-27 |
Family
ID=80787107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542183A Pending JP2025504431A (ja) | 2022-01-17 | 2023-01-17 | レンチウイルスベースの経鼻ワクチンによるＳＡＲＳ－ＣｏＶ－２免疫のブースト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250090655A1 (enExample) |
| EP (1) | EP4466015A1 (enExample) |
| JP (1) | JP2025504431A (enExample) |
| KR (1) | KR20240135619A (enExample) |
| CN (1) | CN118829444A (enExample) |
| AU (1) | AU2023207825A1 (enExample) |
| CA (1) | CA3242669A1 (enExample) |
| TW (1) | TW202337492A (enExample) |
| WO (2) | WO2023135439A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| WO2024050483A1 (en) * | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220152248A (ko) * | 2020-03-13 | 2022-11-15 | 옥스포드 유니버시티 이노베이션 리미티드 | 면역 반응을 유도하기 위한 조성물 및 방법 |
| JP2023535163A (ja) * | 2020-07-15 | 2023-08-16 | アンスティテュ・パストゥール | Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法 |
| CN117120085A (zh) * | 2020-07-15 | 2023-11-24 | 巴斯德研究所 | Sars-cov-2免疫原性组合物、疫苗和方法 |
| WO2022167831A1 (en) * | 2021-02-02 | 2022-08-11 | Institut Pasteur | Sars-cov-2 immunogenic compositions, vaccines, and methods |
-
2022
- 2022-01-17 WO PCT/IB2022/000035 patent/WO2023135439A1/en not_active Ceased
-
2023
- 2023-01-17 CN CN202380017293.1A patent/CN118829444A/zh active Pending
- 2023-01-17 TW TW112102010A patent/TW202337492A/zh unknown
- 2023-01-17 WO PCT/EP2023/051025 patent/WO2023135333A1/en not_active Ceased
- 2023-01-17 AU AU2023207825A patent/AU2023207825A1/en active Pending
- 2023-01-17 CA CA3242669A patent/CA3242669A1/en active Pending
- 2023-01-17 KR KR1020247025586A patent/KR20240135619A/ko active Pending
- 2023-01-17 US US18/726,286 patent/US20250090655A1/en active Pending
- 2023-01-17 JP JP2024542183A patent/JP2025504431A/ja active Pending
- 2023-01-17 EP EP23701288.5A patent/EP4466015A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schulz et al. | Peptide-induced antiviral protection by cytotoxic T cells. | |
| CA2204666C (en) | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector | |
| Lawson et al. | Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge | |
| US9675690B2 (en) | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same | |
| ES2866108T3 (es) | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos | |
| JP2023513720A5 (enExample) | ||
| US20100136052A1 (en) | Replication deficient influenza virus for the expression of heterologous sequences | |
| CA2334857A1 (en) | Interferon inducing genetically engineered attenuated viruses | |
| Haddada et al. | Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice | |
| JP2023526073A5 (enExample) | ||
| CN105658790A (zh) | 疫苗组合物 | |
| RU2005136354A (ru) | Противотуберкулезная вакцина с улучшенной эффективностью | |
| JP2012525410A5 (enExample) | ||
| WO2003031602A1 (en) | The oncolytic microorganisms expressing hsp and uses thereof | |
| MX2013009274A (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| JP2013517800A (ja) | インフルエンザ核酸分子及びそれから作製したワクチン | |
| CN113226364A (zh) | 组合物和方法 | |
| CA2764903C (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| US20190151437A1 (en) | Combination prime: boost therapy | |
| US20110268764A1 (en) | Immune response inducing preparations | |
| Stevceva et al. | Targeting the mucosa: genetically engineered vaccines and mucosal immune responses | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| JP2010528603A (ja) | ネコ抗原のアライグマポックスウイルス発現遺伝子 | |
| JP2023529124A5 (enExample) | ||
| Arnon et al. | Peptide-based synthetic recombinant vaccines with anti-viral efficacy |